

## Review Article

# Vitamin B<sub>12</sub>, Folate, Homocysteine, and Bone Health in Adults and Elderly People: A Systematic Review with Meta-Analyses

**J. P. van Wijngaarden,<sup>1</sup> E. L. Doets,<sup>1</sup> A. Szczecińska,<sup>2</sup> O. W. Souverein,<sup>1</sup> M. E. Duffy,<sup>3</sup> C. Dullemeijer,<sup>1</sup> A. E. J. M. Cavelaars,<sup>1</sup> B. Pietruszka,<sup>2</sup> P. van't Veer,<sup>1</sup> A. Brzozowska,<sup>2</sup> R. A. M. Dhonukshe-Rutten,<sup>1</sup> and C. P. G. M. de Groot<sup>1</sup>**

<sup>1</sup> Division of Human Nutrition, Wageningen University, P.O. Box 8129, 6700 EV Wageningen, The Netherlands

<sup>2</sup> Department of Human Nutrition, Warsaw University of Life Sciences (SGGW), Nowoursynowska 159c, 02 776 Warsaw, Poland

<sup>3</sup> Northern Ireland Centre for Food and Health (NICHE), University of Ulster, Coleraine BT52 1SA, UK

Correspondence should be addressed to J. P. van Wijngaarden; [janneke.vanwijngaarden@wur.nl](mailto:janneke.vanwijngaarden@wur.nl)

Received 4 October 2012; Accepted 23 November 2012

Academic Editor: Christel Lamberg-Allardt

Copyright © 2013 J. P. van Wijngaarden et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Elevated homocysteine levels and low vitamin B<sub>12</sub> and folate levels have been associated with deteriorated bone health. This systematic literature review with dose-response meta-analyses summarizes the available scientific evidence on associations of vitamin B<sub>12</sub>, folate, and homocysteine status with fractures and bone mineral density (BMD). Twenty-seven eligible cross-sectional ( $n = 14$ ) and prospective ( $n = 13$ ) observational studies and one RCT were identified. Meta-analysis on four prospective studies including 7475 people showed a modest decrease in fracture risk of 4% per 50 pmol/L increase in vitamin B<sub>12</sub> levels, which was borderline significant (RR = 0.96, 95% CI = 0.92 to 1.00). Meta-analysis of eight studies including 11511 people showed an increased fracture risk of 4% per  $\mu\text{mol/L}$  increase in homocysteine concentration (RR = 1.04, 95% CI = 1.02 to 1.07). We could not draw a conclusion regarding folate levels and fracture risk, as too few studies investigated this association. Meta-analyses regarding vitamin B<sub>12</sub>, folate and homocysteine levels, and BMD were possible in female populations only and showed no associations. Results from studies regarding BMD that could not be included in the meta-analyses were not univocal.

## 1. Introduction

Osteoporosis is a chronic, multifactorial disorder which is characterized by low bone mass and microarchitectural deterioration of bone tissue [1]. Its major consequence is fractures. Especially hip fractures are frequently associated with institutionalization and increased mortality, and thus with an increased social and economic burden. This burden is expected to increase substantially in Europe in the coming decades due to a rise in life expectancy [2].

Elevated homocysteine concentrations and low vitamin B<sub>12</sub> and folate status have been associated in several studies with lower bone mineral density (BMD) and higher fracture risk in elderly [3–11].

An elevated plasma homocysteine level ( $>15 \mu\text{mol/L}$ ) is prevalent in 30–50% of people older than 60 years [12–14]. The cause is multifactorial; a combination of environmental

and genetic factors, nutrition, lifestyle, and hormonal factors [15]. Vitamin B<sub>12</sub> and folate are major determinants of homocysteine metabolism [16, 17] and supplementation with vitamin B<sub>12</sub> and folic acid has been shown to be effective in normalizing homocysteine levels [18, 19]. Reversing elevated homocysteine levels through folic acid and vitamin B<sub>12</sub> supplementation could theoretically prevent the problem of impaired bone health and osteoporosis. However, at present, no consensus is reached on the magnitude of the association between vitamin B<sub>12</sub>, folate, homocysteine, and bone health nor on the possible effect of vitamin B<sub>12</sub> and folate supplementation on bone health.

Up until now one systematic review including a meta-analysis summarized the evidence on homocysteine and fracture risk, showing that higher homocysteine levels significantly increase the risk of fracture [20]. No meta-analyses are known on the topic of folate and vitamin B<sub>12</sub> in relation

to bone health. The purpose of this review is to provide a systematic overview, where possible including pooled estimates of the dose-response association, of the scientific evidence available from randomized controlled trials (RCTs), prospective cohort, and cross-sectional studies addressing vitamin B<sub>12</sub>, folate, and homocysteine levels in association with bone health, that is, fracture risk and BMD, in adults and elderly people.

## 2. Methods

This systematic review with dose-response meta-analyses was conducted within the scope of the EURRECA (European Micronutrient Recommendations Aligned) Network of Excellence (<http://www.eurreca.org/>) [21]. We followed a standardized methodology which is described in short below.

**2.1. Search Strategy and Selection of Articles.** We conducted systematic literature searches for (1) vitamin B<sub>12</sub>, (2) folate, and (3) homocysteine. The electronic databases MEDLINE, EMBASE, and Cochrane Library Central were searched, using search terms in “MeSH” terms and “title” and “abstract” on study designs in humans, vitamin B<sub>12</sub>, folate, homocysteine, and intake or status. The full Medline search strategy is available online, (see Appendix 1 in Supplementary Material at <http://dx.doi.org/10.1155/2013/486186>).

To be able to use the same search to identify publications on other health related outcomes both in adults and elderly and in younger population groups, no terms were added to limit the search to health outcome or study population. Moreover, by using a broad search we expected a more complete retrieval of relevant publications. In this review only the results on vitamin B<sub>12</sub>, folate, and homocysteine status (i.e., biomarkers measured in serum or plasma) in relation to bone health indicators (fracture risk and BMD) are presented. In addition to the search, reference lists of 10 review articles were checked to identify potentially relevant references that were not identified with the multidatabase search. The search was not limited by language. This review contains studies up to July 2012.

We selected articles in two steps. The first selection step included screening for title and abstract by three independent investigators (J. P. van Wijngaarden, E. L. Doets, SB). In the second selection step, full texts of the selected abstracts were evaluated on basis of predefined inclusion criteria by four investigators (J. P. van Wijngaarden, E. L. Doets, A. Szczecińska, MP).

For the purpose of alignment and quality control 10% of the references in each selection step was screened and selected in duplicate by two investigators independently. Results were compared and discrepancies were resolved by unanimous consensus among all investigators.

Studies were eligible for inclusion if they were conducted in apparently healthy human subjects aged  $\geq 18$  y. Furthermore, studies had to report fracture incidence, fracture risk, or bone mineral density (BMD) as a health outcome and had to report baseline data on the outcome measure.

Observational studies were included if they (1) had a prospective cohort, nested case-control, or cross-sectional design, and (2) addressed serum/plasma concentration of markers indicating vitamin B<sub>12</sub> status (serum/plasma vitamin B<sub>12</sub>, methylmalonic acid (MMA), holotranscobalamin (holoTC)), folate status (serum/plasma folate or erythrocyte folate), or homocysteine status (serum/plasma homocysteine). Intervention studies were included if they (1) had a randomized controlled trial design, (2) studied the effects of vitamin B<sub>12</sub> or folic acid supplements, fortified foods or micronutrient intake from natural food sources and included a placebo or untreated comparison group, and (3) had a minimum intervention duration of six months.

**2.2. Data Extraction and Statistical Analysis.** We extracted data for each of the identified studies on population characteristics, study design, assessment of vitamin B<sub>12</sub>, folate and homocysteine status, and fracture risk or bone mineral density.

Opportunities for meta-analysis were evaluated based on comparability of health outcome and status marker. If less than three comparable studies were available, results were qualitatively described. If three or more comparable studies were available, the results of these individual studies were expressed in a standardized format to allow comparison in the form of a continuous dose-response meta-analysis that pools the regression coefficient ( $\beta$ ) (SE) from multiple adjusted models. We chose to express association measures for serum/plasma vitamin B<sub>12</sub> per 50 pmol/L. When  $\beta$ s were not reported in the original article, we transformed Relative Risk (RR), Hazard Ratio (HR), or Odds Ratio (OR) to  $\beta$ s, using a standardized method [22]. The transformations to obtain  $\beta$ s and SEs and statistical analyses were performed using R statistics version 2.9.2 (<http://www.R-project.org/>), with statistical significance defined as  $P < 0.05$ . HR and OR were considered as RR because the outcome was relatively rare. If articles reported insufficient data (missing data, inconsistencies, or any other uncertainties), we contacted corresponding authors for additional information.

We calculated summary estimates of comparable studies using random effects meta-analysis. Applying the methods of DerSimonian and Laird, the between study variance was estimated which was used to modify the weights for calculating the summary estimate [23]. Residual heterogeneity between studies was evaluated using  $Q$ -statistic and  $I^2$ -statistic.

In total, from 3 searches we identified 11837 potentially relevant articles, of which 9835 articles were excluded based on title and abstract. Of the remaining 2002 articles, 1961 articles were excluded based on full texts, leaving 41 articles. As the searches were partly overlapping and some articles addressed more than one association this resulted in 20 unique articles, 19 observational and 1 intervention. A search update on July 2nd, 2012 resulted in an additional 8 observational studies, which makes a total of 28 included articles. All addressed the association between vitamin B<sub>12</sub>, folate or homocysteine status, and fracture risk or BMD. The flow diagram of the process of screening and selection is shown in Figure 1.




FIGURE 1: Flow diagram of screening and selection.

### 3. Results

#### 3.1. Fractures

**3.1.1. Vitamin B<sub>12</sub>.** Four longitudinal observational studies [3, 24–26], including 7475 elderly people with 3 to 16 years of follow-up and a total of 458 cases addressed the association between serum/plasma vitamin B<sub>12</sub> and fracture (Table 1). Pooled analysis of the association between 50 pmol/L increase in plasma/serum B<sub>12</sub> and change in fracture risk showed an inverse association (RR = 0.96, 95% CI = 0.92 to 1.00) with no heterogeneity between studies ( $I^2 = 0\%$ ,  $P = 0.76$ ) (Figure 2). This indicates that a vitamin B<sub>12</sub> increase of 50 pmol/L tends to decrease the risk of fracture with 4%.

**3.1.2. Folate.** Three longitudinal observational studies examined the association between plasma folate and fractures [24–26] (Table 2). One study showed that women, but not men, with plasma folate in the lowest quartile had a higher

fracture risk (HR 2.40, 95% CI 1.50 to 3.84) compared to the highest (reference) quartile ( $P$  for trend <0.001) [24]. Ravaglia et al. (2005) [26] showed a significant association between low folate status and fracture risk when folate was analyzed as a dichotomous variable (lowest quartile of folate status versus other 3 quartiles), but when analyzed as a continuous variable, no significant association was observed [26]. One study did not observe an association [25].

**3.1.3. Homocysteine.** Eleven longitudinal observational studies examined the association between homocysteine status and fracture incidence [3–5, 25–29] (Table 3). A meta-analysis of eight studies, including 11511 elderly people with 3 to 12.6 years of follow-up and 1353 cases, showed a significantly increased fracture risk with increasing plasma homocysteine ( $\mu\text{mol/L}$ ) (summary estimate RR 1.04, (95% CI: 1.02 to 1.07). Heterogeneity between studies was large ( $I^2 = 60.6\%$ ,  $P = 0.0002$ ) (Figure 3). When hip fractures




FIGURE 2: Forest plot of the association between vitamin B<sub>12</sub> (50 pmol/L) and risk of fracture: Meta-Analysis of 4 observational studies.




FIGURE 3: Forest plot of the association between homocysteine and risk of fracture: Meta-Analysis of 8 observational studies.

(3 studies; [24, 28, 29]) and total fractures (5 studies; [3, 26, 27, 30, 31]) were analyzed separately, the relation remained significant, 1.06 (95% CI: 1.03 to 1.08,  $I^2 = 0\%$ ,  $P = 0.72$ ) and 1.04 (95% CI: 1.00 to 1.08,  $I^2 = 65.0\%$ ,  $P = 0.011$ ).

Three studies that were not included in the meta-analysis also showed significant associations between homocysteine levels and fracture risk. These studies were not included because the necessary data could not be retrieved from the articles; either homocysteine levels were log-transformed [4, 5] or data was not shown for population homocysteine status [25]. Regardless the type of analysis, women and men in the highest homocysteine quartile had a 1.7 to 3.8 higher RR or

HR than those in the lowest or the lowest three quartiles [4, 5, 25].

**3.2. Bone Mineral Density.** In the studies included in this review BMD was measured at various sites in the body (e.g., lumbar spine, femoral neck, radius, hip, and total body). As BMD differs per site in the body, we pooled results per biomarker (serum/plasma vitamin B<sub>12</sub>, folate, and homocysteine) and per site for the three sites generally measured (FN, LS, or total hip), thus resulting in 9 meta-analyses. Betas of the individual studies are shown in Tables 1, 2, and 3. The studies included in the meta-analyses took only women into account.

TABLE 1: Studies regarding the association between vitamin B<sub>12</sub> and bone health.

Author Year	Study characteristics	Population characteristics: N (% men) Age (y) ± SD	Vitamin B <sub>12</sub> status pmol/L* Mean ± SD	Outcome	Association type	Results*
Dhonukshe-Rutten et al. 2005 [3]	Duration of follow-up (when applicable) Country <i>Risk of bias</i> Cohort (3 y) The Netherlands <i>High risk</i>	1253 (48%) 75.5 ± 6.6	♀: 289 ± 99 ♂: 268 ± 89	Fracture (verified by physician or radiograph)	β (SE) for association vitB <sub>12</sub> -fracture (per 50 pmol/L)	♀: -0.09 (0.06) <sup>a,1</sup> ♂: 0.02 (0.08) <sup>a,1</sup>
Gjesdal et al. 2007 [24]	Cohort (12.6 y) Norway <i>Low risk</i>	4761 (45%) 65–67 at baseline	♀: 386.4 ± 372.0 ♂: 359.3 ± 276.2	Hip fracture (verified by hospital discharge diagnoses)	β (SE) for association vitB <sub>12</sub> -hip fracture (per 50 pmol/L)	♀: -0.03 (0.03) <sup>b,2</sup> ♂: -0.06 (0.05) <sup>b,2</sup>
McLean et al. 2008 [25]	Cohort (16 y) USA <i>Low risk</i>	823 (41%) 75.3 ± 4.9	Deficient (<148): ♀9%/♂14.0% Low (148–257.9): ♀24.3%/♂32.5% Normal (≥258): ♀66.7%/♂53.5%	Hip fracture (verified by review medical records)	β (SE) for association vitB <sub>12</sub> -hip fracture (per 50 pmol/L)	♀: -0.09 (0.06) <sup>c,1</sup> ♂: -0.09 (0.11) <sup>c,1</sup>
Ravaglia et al. 2005 [26]	Cohort (4 y) Italy <i>Moderate risk</i>	702 (47%) 73.0 ± 6.0	Geometric mean (95% CI) 249.1 (203–272)	Fracture (verified by review medical records)	β (SE) for association vitB <sub>12</sub> -fracture (per 50 pmol/L)	0.04 (0.08) <sup>d,2</sup>
Bozkurt et al. 2009 [32]	Cross-sectional Turkey <i>High risk</i>	178 (0%) 53.5 ± 8.0	247.7 ± 85.4	BMD: LS, FN [DXA]	Logistic regression for FN, LS and FN + LS combined for vitB <sub>12</sub> status under the quintile value. β (SE) + P value	LS: -2.3 (0.9) P = 0.017 FN: -0.4 (0.9) P = 0.669 LS + FN: 1.8 (0.8) P = 0.045 <sup>e</sup>
Bucciarelli et al. 2010 [33]	Cross-sectional Italy <i>Moderate risk</i>	446 (0%) 65.1 ± 9.4	(geometric mean ± SD) 399.1 ± 1.6	BMD: FN, LS, TH [DXA, Prodigy, GE, Lunar]	β for association vitB <sub>12</sub> -TH BMD β (SE) (per 50 pmol/L)	-0.00105 (0.939) <sup>f,2</sup>
Cagnacci et al. 2008 [34]	Cohort (5 y) Italy <i>Moderate risk</i>	117 (0%) 54.4 ± 0.5	(Mean ± SE) 548.5 ± 40.5	BMD: LS [DXA: Lunar DPX]	Regression for vitB <sub>12</sub> -BMD change β (SE) P value	-0.003 (0.012) P = 0.784 <sup>g</sup>
Dhonukshe-Rutten et al. 2003 [35]	Cross-sectional The Netherlands <i>Moderate risk</i>	194 (26%) 78.3 ± 5.5	♀288 ± 131 ♂238 ± 95	BMD: whole body [DXA, Lunar DPX-L]	Multivariate regression, β for association vitB <sub>12</sub> -BMD β (95% CI) in women	♀: 12.3·10 <sup>-5</sup> (0.2·10 <sup>-5</sup> – 2.4·10 <sup>-4</sup> ) <sup>h</sup>
Gjesdal et al. 2006 [10]	Cross-sectional Norway <i>Moderate risk</i>	5329 (43%) middle aged: 47–50 Older: 71–75	♀393.4 ± 235.8 ♂374.6 ± 230.7	BMD: TH [DXA, Lunar EXPERT-XL]	OR (95% CI) for low BMD per category vitB <sub>12</sub> status 1: <230 pmol/L 2: 230.0–279.9 pmol/L 3: 280.0–414.9 pmol/L 4: ≥415.0 pmol/L + P for trend	♀: 1: 0.97 (0.68–1.37) ♂: 1.14 (0.80–1.62) 3: 1.02 (0.82–1.27) 4: 1.00 (reference) P for trend = 0.61 P for trend = 0.25 <sup>i</sup>



TABLE 1: Continued.

Author Year	Study characteristics Duration of follow-up (when applicable) Country <i>Risk of bias</i>	Population characteristics: N (% men) Age (y) $\pm$ SD	Vitamin B <sub>12</sub> status pmol/L* Mean $\pm$ SD	Outcome	Association type	Results*
Golbahar et al. 2004 [9]	Cross-sectional Iran <i>Moderate risk</i>	271 (0%) 60.8 $\pm$ 6.8	(geometric mean $\pm$ SD) 339.5 $\pm$ 247.6	BMD: FN, LS [DXA, Lunar DPX-L]	$\beta$ (SE) for association vitB <sub>12</sub> -BMD (per 50 pmol/L)	FN: 0.0002 (0.07) <sup>2</sup> LS: 0.0114 (0.14) <sup>2</sup>
Haliloglu et al. 2010 [36]	Cross-sectional Turkey <i>Moderate risk</i>	120 (0%) 54.4 $\pm$ 1.1	Osteoporotic: 216.0 $\pm$ 135.1 Osteopenic: 190.8 $\pm$ 97.4 Normal BMD: 251.0 $\pm$ 205.8	BMD: LS [DXA, Lunar DPX-L]	ANOVA for difference in vitB <sub>12</sub> status per BMD group compared to normal BMD group	No sign differences in vitB <sub>12</sub> status between BMD groups
Krivosikova et al. 2010 [37]	Cross-sectional Slovakia <i>High risk</i>	272 (0%) 41.3 $\pm$ 19.8	273.2 $\pm$ 152.7	BMD: FN, LS, trochanter, TH [DXA, Lunar DPX-L]	Stepwise multivariate linear regression, $\beta$ for association vitB <sub>12</sub> -BMD. $\beta$ (SE) <i>P</i> value (per 50 pmol/L)	FN: -2.0 (2.73) <sup>j,2</sup> LS: -1.15 (1.42) <sup>j,2</sup> TH: -0.5 (3.03) <sup>j,2</sup>
Morris et al. 2005 [7]	Cross-sectional USA <i>Low risk</i>	1550 (48%) 68	Geometric mean (95% CI) Osteoporosis: 271 (243-302) Osteopenia: 309 (293-325) Normal: 310 (297-323) Serum MMA (nmol/L) Osteoporosis: 305 (276-337) Osteopenia: 251 (234-269) Normal: 241 (212-274)	BMD: Trochanter, intertrochanter, FN, Ward's triangle, TH [DXA, Hologic QDR-1000]	OR (95% CI) for mean BMD in relation to quartile categories of vitB <sub>12</sub> and MMA status + <i>P</i> for trend. Category medians:  B <sub>12</sub> MMA (pmol/L): (nmol/L); Q1: 182 157 Q2: 268 206 Q3: 349 272 Q4: 495 415	Vit B <sub>12</sub> : Q1: 2.0 1.0 (1.0-3.9) Q2: 1.3 3.5 (0.6-2.7) (1.4-8.5) Q3: 1.7 5.2 (0.8-3.3) (2.0-13.1) Q4: 1.0 7.2 (reference) (3.4-15.2) <i>P</i> for trend = 0.09 <0.001 <sup>k</sup>
Naharci et al. 2012 [38]	Cross-sectional Turkey <i>Moderate risk</i>	264 (100%) 77.0 $\pm$ 6.0	26.7% low (<148, group I) 39.1% borderline (148-221, group II) 34.2% normal (>221, group III)	BMD: FN, TH, trochanter, inter-trochanter [DXA, hologic QDR-4500]	Anova for differences in FN BMD between groups of serum vitB <sub>12</sub>	Sign differences FN BMD group I and II ( <i>P</i> = 0.013) group I and III ( <i>P</i> < 0.001) group II and III ( <i>P</i> = 0.003) FN BMD was positively correlated with serum vitB <sub>12</sub> ( <i>r</i> = 0.362, <i>P</i> < 0.001)
Ouzzif et al. 2012 [39]	Cross-sectional Morocco <i>Moderate risk</i>	188 (0%) 57.8 $\pm$ 8.5	360.4 $\pm$ 149.2	BMD: FN, LS, TH, trochanter [DXA, Lunar prodigy]	Multivariate regression, $\beta$ for association vitB <sub>12</sub> -BMD $\beta$ (SE) (per 50 pmol/L) <i>P</i> value	LS: <i>P</i> = 0.160 <sup>l,2</sup> -7.85 (0.25) TH: <i>P</i> = 0.007 <sup>l,2</sup> -11.65 (0.02)

TABLE 1: Continued.

Author Year	Study characteristics Duration of follow-up (when applicable) Country <i>Risk of bias</i>	Population characteristics: N (% men) Age (y) $\pm$ SD	Vitamin B <sub>12</sub> status pmol/L* Mean $\pm$ SD	Outcome	Association type	Results*
Rumbak et al. 2012 [40]	Cross-sectional Croatia <i>Low risk</i>	131 (0%) 54.0 $\pm$ 4.9	239.6 $\pm$ 97.0	BMD: FN, LS, TH, radius [DXA, Lunar-prodigy]	Stepwise multivariate regression, $\beta$ for association vitB <sub>12</sub> -BMD for pre- and postmenopausal women $\beta$ (SE) P value (per 50 pmol/L)	Premenopausal: LS: -3.39 (8.91) P = 0.709 <sup>m,2</sup> FN: 7.45 (10.07) P = 0.467 <sup>m,2</sup> TH: -1.36 (7.53) P = 0.862 <sup>m,2</sup> Postmenopausal: LS: 7.45 (8.98) P = 0.411 <sup>m,2</sup> FN: 12.20 (8.97) P = 0.180 <sup>m,2</sup> TH: 8.81 (8.63) P = 0.314 <sup>m,2</sup>
Stone et al. 2004 [11]	Cohort (5.9 y) USA <i>Low risk</i>	83 (0%) 71.1 $\pm$ 4.4	352 $\pm$ 174	BMD: TH, FN (change) [DXA, Hologic QDR-1000]	t-test for difference in BMD change between low and normal vitB <sub>12</sub> status	Participants with low vitB <sub>12</sub> ( $\leq$ 207 pmol/L) had a more rapid decline in BMD (-1.91%/year) than part. with normal vitB <sub>12</sub> (-0.10%/year), P < 0.05
Tucker et al. 2005 [6]	Cross-sectional USA <i>Low risk</i>	2576 (44%) 58.8 $\pm$ 9.5	Distribution per category of plasma vitB <sub>12</sub> status 1: $\bar{q}$ 4.4%/ $\bar{\sigma}$ 4.7% $\leq$ 148 2: $\bar{q}$ 6.9%/ $\bar{\sigma}$ 7.8% >148-185 3: $\bar{q}$ 25.4%/ $\bar{\sigma}$ 28.2% >185-259 4: $\bar{q}$ 63.3%/ $\bar{\sigma}$ 59.3% >259	BMD: FN, LS, TH, Trochanter, Ward [DXA, Lunar DPX-L] 1	Differences in BMD per category of plasma vitB <sub>12</sub> level, relative to category 1	$\bar{q}$ : FN: no differences $\bar{q}$ : LS: vitB <sub>12</sub> in cat 2 (P < 0.10), 3, 4 (P < 0.05) was assoc. with better BMD $\bar{q}$ : TH: vitB <sub>12</sub> in cat 3, 4 (P < 0.10) was assoc. with better BMD $\bar{\sigma}$ : FN: vitB <sub>12</sub> in cat 2, 3, 4 was assoc. with better BMD (P < 0.05) $\bar{\sigma}$ : LS: no differences $\bar{\sigma}$ : TH: vitB <sub>12</sub> in cat 2 (P < 0.10), 3, 4 (P < 0.05) was assoc. with better BMD <sup>n</sup>

\* Serum/plasma vitamin B<sub>12</sub> concentrations were converted to pmol/L if applicable, using the following equation: 1 pg/mL = 1 ng/L = 0.738 pmol/L. subsequent outcomes were also converted. Where possible, subgroups were combined. BMD sites: LS: Lumbar Spine, FN: Femoral Neck, TH: Total Hip.

<sup>1</sup>  $\beta$ (SE) as calculated from data provided by author; <sup>2</sup>  $\beta$  (SE) as calculated from presented data.

<sup>a</sup> adjusted for age, BMI, smoking, recurrent fallings; <sup>b</sup> adjusted for age, BMI, smoking, coffee intake, physical activity, vit D use, educational level, estrogen use in women; <sup>c</sup> adjusted for sex, age, height, weight, estrogen use in women; <sup>d</sup> adjusted for age, sex, education, osteoporosis drugs, creatinine, tHcy; <sup>e</sup> adjusted for duration of menopause, smoking, BMI, folic acid levels, tHcy levels; <sup>f</sup> adjusted for age, BMI, logtHcy, logFolate, creatinine clearance, smoking, alcohol intake; <sup>g</sup> Adjusted for age, weight, weight change; <sup>h</sup> adjusted for weight, height, energy intake; <sup>i</sup> adjusted for smoking, BMI, creatinin, coffee intake, physical activity, use of estrogen therapy; <sup>j</sup> adjusted for age, folate, tHcy, PTH, CTx, Ca, Cr; <sup>k</sup> Adjusted for age, sex, ethnicity, BMI, smoking, physical activity, creatinin, alcohol, coffee, energy, calcium, vitamin D zinc intake; <sup>l</sup> adjusted for age, BMI, tHcy and folate; <sup>m</sup> adjusted for Age, BMI, smoking, alcohol, physical activity, tHcy, Folate; <sup>n</sup> adjusted for energy, calcium, vitamin D intake, BMI, height, smoking, age, physical activity, calcium supplement, vitamin D supplement, alcohol, osteoporosis medication, season of measurement.

TABLE 2: Studies regarding the association between folate and bone health.

Author Year	Study characteristics Duration of follow-up (when applicable) Country Risk of bias	Population characteristics: N (%men) Age (y) $\pm$ SD	Folate status (nmol/L)* Mean $\pm$ SD	Outcome	Association type	Results*
Gjesdal et al. 2007 [24]	Cohort (12.6 y) Norway Low risk	4761 (45%) 65–67 at baseline	$\varnothing$ 6.0 $\pm$ 3.5 $\sigma$ 5.2 $\pm$ 2.7	Hip fracture (verified by hospital discharge diagnoses)	HR for hip fracture according to folate status 1: <2.9 2: 2.9–3.8 3: 3.9–6.5 4: $\geq$ 6.6	$\varnothing$ : 1.240 (1.50–3.84) 2: 1.15 (0.68–1.94) 3: 1.02 (0.39–1.62) 4: 1.00 (0.45–1.46) (reference) <sup>a</sup>
McLean et al. 2008 [25]	Cohort (16 y) USA Low risk	960 (41%) 75.3 $\pm$ 4.9	Not shown	Hip fracture (verified by review medical records)	HR for hip fracture according to folate status Normal: $\geq$ 11 Low: 7–10.9 Deficient: <7	Normal: 1.00 (reference) Low: 0.76 (0.43, 1.32) Deficient: 1.38 (0.91, 2.09) <sup>b</sup>
Ravaglia et al. 2005 [26]	Cohort (4 y) Italy Moderate risk	702 (47%) 73.0 $\pm$ 6.0	11.7 (9.0–12.2) mean (95% CI)	Fracture (verified by review medical records)	OR (95% CI) for risk of fracture at follow-up for each increment of 1 sd in the log-transformed serum folate value	0.83 (0.59–1.19) <sup>c</sup>
Baines et al. 2007 [41]	Cross-sectional Great Britain High risk	328 (0%) 67.5 (40–85) mean (range)	Osteoporosis: 8.1 $\pm$ 8.7 <sup>#</sup> Osteopenia: 10.2 $\pm$ 4.6 Normal: 9.4 $\pm$ 6.3	BMD: os calcis/heel bone [PIXI, GE Lunar]	ANOVA for difference between the normal, osteopenia and osteoporosis group	FA status was significantly different between osteoporotic and osteopenic group (P = 0.049)
Bozkurt et al. 2009 [32]	Cross-sectional Turkey High risk	178 (0%) 53.5 $\pm$ 8.0	24.9 $\pm$ 7.9	BMD: FN, LS [DXA]	Logistic regression for FN, LS and FN + LS combined. $\beta$ (SE) + P value for assoc. BMD-folate status under the median value	LS: -0.2 (0.2) P = 0.417 FN: -0.04 (0.2) P = 0.835 LS + FN: -0.03 (0.2) P = 0.896 <sup>d</sup>
Bucciarelli et al. 2010 [33]	Cross-sectional Italy Moderate risk	446 (0%) 65.1 $\pm$ 9.4	(geometric mean $\pm$ SD) 3.8 $\pm$ 1.6	BMD: FN, LS, TH [DXA, Prodigy, GE, Lunar]	$\beta$ for association folate-TH BMD $\beta$ (SE)	0.004 (0.018) <sup>e,2</sup>
Cagnacci et al. 2008 [34]	Cohort (5 y) Italy Moderate risk	117 (0%) 54.4 $\pm$ 0.5	(Mean $\pm$ SE) 20.6 $\pm$ 1.4	BMD: LS [DXA: Lunar DPX]	Regression analysis for folate-BMD change $\beta$ (SE) + P value	1.602 (0.803) P = 0.048 <sup>f</sup>
Cagnacci et al. 2003 [8]	Cross-sectional Italy Moderate risk	161 (0%) 53.3 $\pm$ 1.04	(Mean $\pm$ SE) 21.5 $\pm$ 4.3	BMD: LS [DXA: Lunar DPX]	Regression analysis, r (P value) for association folate-BMD	r = 0.254 (P < 0.002)



TABLE 2: Continued.

Author Year	Study characteristics Duration of follow-up (when applicable) Country <i>Risk of bias</i>	Population characteristics: <i>N</i> (%men) Age (y) ± SD	Folate status (nmol/L)* Mean ± SD	Outcome	Association type	Results*
Gjesdal et al. 2006 [10]	Cross-sectional Norway <i>Moderate risk</i>	5329 (43%) middle aged: 47–50 Older: 71–75	♀8.9 ± 7.1 ♂7.3 ± 4.6	BMD: TH [DXA, Lunar EXPERT-XL]	OR (95% CI) for low BMD per category folate status: 1: FA < 3.8 nmol/L 2: FA 3.8–4.9 nmol/L 3: FA 5.0–8.4 nmol/L 4: FA ≥ 8.5 nmol/L + <i>P</i> for trend Multivariate regression for folate-BMD β (SE) (per 50 nmol/L)	♀: 1.55 (1.07–2.23) 2: 1.18 (0.86–1.63) 3: 1.24 (0.99–1.56) 4: 1.00 (reference) <i>P</i> for trend = 0.02 Elderly women: β = 0.05 (0.02) <sup>g,2</sup>
Golbahar et al. 2004 [9]	Cross-sectional Iran <i>Moderate risk</i>	271 (0%) 60.8 ± 6.8	(geometric mean ± SD) 11.6 ± 6.5	BMD: FN, LS [DXA, Lunar DPX-L]	β for association folate-BMD β (SE)	FN: 0.008 (0.019) <sup>h,2</sup> LS: 0.010 (0.018) <sup>i,2</sup>
Haliloglu et al. 2010 [36]	Cross-sectional Turkey <i>Moderate risk</i>	120 (0%) 54.4 ± 1.1	Osteoporotic: 12.2 ± 6.3 Osteopenic: 15.4 ± 7.4 Normal: 15.8 ± 8.3	BMD: LS [DXA, Lunar DPX-L]	ANOVA for difference in folate status per BMD group (osteoporotic, osteopenic, compared to normal BMD group)	No significant differences in folate status between BMD groups
Krivosikova et al. 2010 [37]	Cross-sectional Slovakia <i>High risk</i>	272 (0%) 41.3 ± 19.8	23.8 ± 9.6	BMD: FN, LS, trochanter, TH [DXA, Lunar DPX-L]	Stepwise multivariate linear regression, β for association folate-BMD, β (SE) <i>P</i> value	FN: -0.028 (0.054) <i>P</i> = 0.606 <sup>j,2</sup> LS: -0.001 (0.067) <i>P</i> = 0.988 <sup>j,2</sup> TH: -0.032 (0.060) <i>P</i> = 0.595 <sup>j,2</sup>
Morris et al. 2005 [7]	Cross-sectional USA <i>Low risk</i>	1550 (47%) 68	Osteoporosis: 17.2 (15.4–19.2) Osteopenia: 17.2 (16.0–18.5) Normal: 16.7 (15.3–18.3) Geometric mean (95% CI)	BMD: Trochanter, intertrochanter, FN, Ward's triangle, TH [DXA, Hologic QDR-1000]	OR (95% CI) for mean BMD in relation to quartile categories of folate status + <i>P</i> for trend Category median (nmol/L): Q1: 8.0 Q2: 12.4 Q3: 20.3 Q4: 38.9	Q1: 1.1 (0.5–2.3) Q2: 1.1 (0.05–2.9) Q3: 1.5 (0.7–3.4) Q4: 1.0 (reference) <i>P</i> for trend = 0.83 <sup>k</sup>

TABLE 2: Continued.

Author Year	Study characteristics Duration of follow-up (when applicable) Country <i>Risk of bias</i>	Population characteristics: N (%men) Age (y) ± SD	Folate status (nmol/L)* Mean ± SD	Outcome	Association type	Results*
Naharci et al. 2012 [38]	Cross-sectional Turkey <i>Moderate risk</i>	264 (100%) 77.0 ± 6.0	low (<7.0, group I): 0.0% borderline (7.0–10.9, group II): 9.2% normal (>10.9, group III): 90.8%	BMD: FN, TH, trochanter, intertrochanter [DXA, hologic QDR-4500]	Independent sample <i>t</i> -test for differences in FN BMD between group II and III of serum folate	No significant differences in BMD (all sites) between group II and III of folate status
Ouzzif et al. 2012 [39]	Cross-sectional Morocco <i>Moderate risk</i>	188 (0%) 57.8 ± 8.5	15.6 ± 6.8	BMD: FN, LS, TH, trochanter [DXA, Lunar prodigy]	Multivariate regression, $\beta$ for association folate-BMD $\beta$ (SE) + <i>P</i> value	LS: 0.007 (0.002) <i>P</i> = 0.808 <sup>L</sup> TH: 0.006 (0.001) <i>P</i> = 0.834 <sup>L</sup>
Rumbak et al. 2012 [40]	Cross-sectional Croatia <i>Low risk</i>	131 (0%) 54.0 ± 4.9	22.4 ± 7.5	BMD: FN, LS, TH, radius [DXA, Lunar-prodigy]	Stepwise multivariate regression, $\beta$ for association folate-BMD $\beta$ + <i>P</i> value	Premenopausal: LS: 3.31 (4.73) <i>P</i> = 0.490 <sup>m,2</sup> FN: 1.32 (4.90) <i>P</i> = 0.791 <sup>m,2</sup> TH: 2.87 (4.35) <i>P</i> = 0.516 <sup>m,2</sup> Postmenopausal: LS: -3.75 (3.47) <i>P</i> = 0.284 <sup>m,2</sup> FN: -1.32 (3.15) <i>P</i> = 0.679 <sup>m,2</sup> TH: 0.66 (3.89) <i>P</i> = 0.862 <sup>m,2</sup>

\* Serum/plasma folate concentrations were converted to nmol/L if applicable, using the following equation: 1 ng/ml = 2.266 nmol/L. Subsequent outcomes were also converted. Where possible, subgroups were combined. BMD sites—LS: Lumbar Spine, FN: Femoral Neck, TH: Total Hip. <sup>a</sup> Total Hip <sup>a</sup> data presented in article as  $\mu\text{mol/L}$ , this is presumably a typing error and should be nmol/L.

<sup>b</sup>  $\beta$  (SE) as calculated from data provided by author; <sup>2</sup>  $\beta$  (SE) as calculated from presented data.

<sup>a</sup> adjusted for age, BMI, smoking, coffee intake, physical activity, vit D use, educational level, estrogen use in women; <sup>b</sup> adjusted for sex, age, height, weight, estrogen use in women; <sup>c</sup> adjusted for age, gender, education, osteoporosis drug, serum creatinine, tHcy; <sup>d</sup> Adjusted for duration of menopause, smoking, BMI, B<sub>12</sub>, tHcy; <sup>e</sup> adjusted for age, BMI, log<sub>10</sub>Hcy, logB<sub>12</sub>, creatinine clearance, smoking, alcohol intake;

<sup>f</sup> Adjusted for age, weight, weight change; <sup>g</sup> Adjusted for smoking, BMI, creatinin, coffee intake, physical activity, use of estrogen therapy; <sup>h</sup> adjusted for age, BMI, alkaline phosphatase; <sup>i</sup> adjusted for years since menopause, BMI, alkaline phosphatase, creatinine; <sup>j</sup> adjusted for age, B<sub>12</sub>, tHcy, PTH, CTx, Ca, Cr; <sup>k</sup> Adjusted for age, sex, ethnicity, BMI, smoking; physical activity, creatinin, alcohol, coffee, energy, calcium, vitamin D zinc intake; <sup>L</sup> adjusted for age, BMI, tHcy, B<sub>12</sub>; <sup>m</sup> adjusted for Age, BMI, smoking, alcohol, physical activity, tHcy, B<sub>12</sub>.

TABLE 3: Studies regarding the association between homocysteine and bone health.

Author Year	Study characteristics Duration of follow-up (when applicable) Country Risk of bias	Population characteristics: N (%men) Age (y) $\pm$ SD	Homocysteine status ( $\mu$ mol/L) Mean $\pm$ SD	Outcome	Association type	Results
Dhonukshe-Rutten et al. 2005 [3]	Cohort (3y) The Netherlands High risk	1253 (48%) 75.5 $\pm$ 6.6	geometric mean (10–90 percentile) ♀: 13.0 (8.6–19.7) ♂: 14.9 (10.2–22.8)	Fracture (verified by physician or radiograph)	$\beta$ (SE) for association tHcy-fracture	♀: 0.07 (0.05) <sup>a,2</sup> ♂: 0.11 (0.05) <sup>a,2</sup>
Enneman et al. 2012 [30]	Cohort (7y) The Netherlands Moderate risk	503 (0%) 68.5 (61.3–74.9) Median (range)	Median (range) 9.3 (3.5–29.7)	Fracture (verified by physician)	$\beta$ (SE) for association tHcy-fracture	0.05 (0.02) <sup>b,2</sup>
Gerdhem et al. 2007 [29]	Cohort (7y) Sweden Low risk	996 (0%) 75	Median (IQR) 14.1 (11.6–17.3)	Hip fracture (verified by radiograph)	$\beta$ (SE) for association tHcy-hip fracture	0.07 (0.03) <sup>c,2</sup>
Gjesdal et al. 2007 [24]	Cohort (12.6y) Norway Low risk	4761 (45%) 65–67 at baseline	♀: 11.6 $\pm$ 4.2 ♂: 13.1 $\pm$ 5.8	Hip fracture (verified by hospital discharge diagnoses)	$\beta$ (SE) for association tHcy-hip fracture	♀: 0.05 (0.02) <sup>d,2</sup> ♂: 0.03 (0.03) <sup>d,2</sup>
Leboff et al. 2009 [28]	Nested case-control USA Moderate risk	800 (0%) 70.8 $\pm$ 6.2	11.2 $\pm$ 4.1	Hip fracture (verified by radiograph)	$\beta$ (SE) for association tHcy-Hip fracture	0.07 (0.03) <sup>e,2</sup>
McLean et al. 2004 [4]	Cohort (♀15y; ♂12.3y) USA Moderate risk	1999 (41%) 70.0 $\pm$ 7.0	♀: 12.1 $\pm$ 5.3 ♂: 13.4 $\pm$ 9.1	Hip fracture (verified by review medical records)	HR (95% CI) for hip fracture risk by quartiles of tHcy. Mean tHcy per quartile: ♀: ♂: Q1: 7.6 $\pm$ 1.0 8.5 $\pm$ 0.9 Q2: 9.9 $\pm$ 0.7 11.0 $\pm$ 0.6 Q3: 12.2 $\pm$ 0.7 13.4 $\pm$ 0.9 Q4: 18.6 $\pm$ 6.4 20.8 $\pm$ 15.7	♀: 1.00 (reference) ♂: 1.57 (0.45–5.14) 2.07 (0.70–6.09) 3.84 (1.38–10.70)
McLean et al. 2008 [25]	Cohort (16y) USA Low risk	979 (41%) 75.3 $\pm$ 4.9	73.7% normal ( $\leq$ 14 $\mu$ mol/l) 26.3% high (>14)	Hip fracture (verified by review medical records)	HR (95% CI) for high plasma tHcy ( $\geq$ 14 $\mu$ mol/L) versus normal tHcy	Normal 1.00 (reference) High 1.69 (1.12–2.55) <sup>g</sup>

TABLE 3: Continued.

Author Year	Study characteristics Duration of follow-up (when applicable) Country <i>Risk of bias</i>	Population characteristics: N (%men) Age (y) $\pm$ SD	Homocysteine status ( $\mu\text{mol/L}$ ) Mean $\pm$ SD	Outcome	Association type	Results
Van Meurs et al. 2004 [5]	Cohort (4.7 y) The Netherlands <i>High risk</i>	2406 (47%) 73.9 $\pm$ 7.8	14.3 $\pm$ 5.8	Fracture (verified by physician)	RR (95% CI) for fracture for each increment of 1 SD in the natural log-transformed tHcy value.	1.4 (1.2–1.6) <sup>h</sup>
P�rier et al. 2007 [27]	Cohort (10 y) France <i>Moderate risk</i>	671 (0%) 61.6 $\pm$ 8.4	10.6 $\pm$ 3.5	Fracture (verified by radiograph or surgical report)	$\beta$ (SE) for association tHcy-fracture	0.02 (0.02) <sup>i,3</sup>
Ravaglia et al. 2005 [26]	Cohort (4 y) Italy <i>Moderate risk</i>	702 (47%) 73.0 $\pm$ 6.0	Geometric mean (95% CI) 12.7 (11.3–15.1)	Fracture (verified by review medical records)	$\beta$ (SE) for association tHcy-fracture	0.09 (0.05) <sup>j,2</sup>
Zhu et al. 2009 [31]	Cohort (5 y) Australia <i>Moderate risk</i>	1213 (0%) 75.2 $\pm$ 2.7	12.1 $\pm$ 4.6	Fracture (verified by radiograph)	$\beta$ (SE) for association tHcy-fracture	–0.002 (0.006) <sup>k,2</sup>
Baines et al. 2007 [41]	Cross-sectional Great Britain <i>High risk</i>	328 (0%) 67.5 (40–85) mean (range)	12.3 $\pm$ 5.4	BMD: os calcis/heel bone [PIXI, GELunar]	Stepwise multivariate linear regression $\beta$ (SE) + <i>P</i> value for association log tHcy-BMD	–1.548 (0.607) <i>P</i> = 0.011 <sup>l</sup>
Bozkurt et al. 2009 [32]	Cross-sectional Turkey <i>High risk</i>	178 (0%) 53.5 $\pm$ 8.0	10.4 $\pm$ 3.0 <sup>*</sup>	BMD: FN/LS [DXA]	Logistic regression for FN, LS and FN + LS combined. $\beta$ (SE) + <i>P</i> value for association hcy level under the median value-BMD	LS: –0.8 (0.5) <i>P</i> = 0.140 FN: –0.5 (0.6) <i>P</i> = 0.408 LS + FN: –1.3 (0.6) <i>P</i> = 0.032 <sup>m</sup>
Bucciarelli et al. 2010 [33]	Cross-sectional Italy <i>Moderate risk</i>	446 (0%) 65.1 $\pm$ 9.4	(geometric mean $\pm$ SD) 10.6 $\pm$ 1.3	BMD: FN, LS, TH [DXA, Prodigy, GE, Lunar]	Multivariate linear regression $\beta$ for association log tHcy-total femur BMD. $\beta$ (SE) <i>P</i> value	–0.050 (0.025) <i>P</i> = 0.048 <sup>n,2</sup>
Cagnacci et al. 2008 [34]	Cohort Italy <i>Moderate risk</i>	117 (0%) 54.4 $\pm$ 0.5	(Mean $\pm$ SE) 10.7 $\pm$ 0.5	BMD: LS [DXA: Lunar DPX]	Regression analysis for Hcy-BMD change $\beta$ (SE) + <i>P</i> value	–0.825 (1.09) <i>P</i> = 0.449 <sup>o</sup>
Cagnacci et al. 2003 [8]	Cross-sectional Italy <i>Moderate risk</i>	161 (0%) 53.3 $\pm$ 1.0	10.5 $\pm$ 0.9	BMD: LS [DXA: Lunar DPX]	Regression analysis, $\beta$ for association Hcy-BMD	$\beta$ = –0.002 <sup>p,1</sup>
Gerdhem et al. 2007 [29]	Cohort (cross sect data) Sweden <i>Low risk</i>	996 (0%) 75	Median (IQR) 14.1 (11.6–17.3)	BMD: FN, LS, TH [DXA: Lunar DPX-L]	<i>t</i> -test for difference in BMD ( <i>P</i> value) between highest quartile of hcy versus all others	FN: Q4 versus Q1–3: <i>P</i> = 0.032 LS: Q4 versus Q1–3: <i>P</i> = 0.821 TH: Q4 versus Q1–3: <i>P</i> = 0.001

TABLE 3: Continued.

Author Year	Study characteristics Duration of follow-up (when applicable) Country <i>Risk of bias</i>	Population characteristics: N (%men) Age (y) ± SD	Homocysteine status ( $\mu\text{mol/L}$ ) Mean ± SD	Outcome	Association type	Results
Gjesdal et al. 2006 [10]	Cross-sectional Norway <i>Moderate risk</i>	5329 (43%) middle aged: 47–50 Older: 71–75	$\bar{x}$ : 10.2 ± 4.5 $\sigma^2$ : 11.8 ± 3.9	BMD: TH [DXA, Lunar EXPERT-XL]	Multivariate regression, $\beta$ for association tHcy-BMD (P value) for middle aged and elderly women. (Data men not shown) OR (95% CI) for low BMD per category tHcy status + P for trend:	Mid. aged women: $\beta = 0.004$ (P < 0.001) elderly women: $\beta = 0.003$ (P < 0.001) <sup>4</sup>  $\bar{x}$ : 1.00 (reference) $\sigma^2$ : 1.00 (reference) 2: 1.14 (0.74–1.37) 3: 1.30 (0.90–1.44) 4: 2.19 (0.79–1.60) 1.02 (1.48–3.25) P for trend = 0.001 0.72 <sup>4</sup>
Golbahar et al. 2004 [9]	Cross-sectional Iran <i>Moderate risk</i>	271 (0%) 60.8 ± 6.8	geometric mean (95% CI) 13.7 (7–14)	BMD: FN, LS [DXA, Lunar DPX-L]	$\beta$ for association tHcy-BMD $\beta$ (SE)	FN: -0.012 (0.023) <sup>2</sup> LS: -0.010 (0.024) <sup>2</sup>
Haliloglu et al. 2010 [36]	Cross-sectional Turkey <i>Moderate risk</i>	120 (0%) 54.4 ± 1.1	Osteoporotic: 15.0 ± 4.6 Osteopenic: 14.2 ± 3.7 Normal: 11.2 ± 2.6	BMD: LS [DXA, Lunar DPX-L]	ANOVA for difference in tHcy status per BMD group	tHcy was sign. higher in the osteoporotic group versus normal group (P < 0.05)
Krivosikova et al. 2010 [37]	Cross-sectional Slovakia <i>High risk</i>	272 (0%) 41.3 ± 19.8	( $\mu\text{mol/L}$ ) 14.6 ± 5.5	BMD: FN, LS, trochanter, TH [DXA, Lunar DPX-L]	Stepwise multivariate linear regression, $\beta$ for association tHcy-BMD. $\beta$ (SE) P value	FN: -0.093 (0.06) P = 0.100 <sup>1,2</sup> LS: 0.003 (0.07) P = 0.965 <sup>1,2</sup> TH: -0.134 (0.06) P = 0.033 <sup>1,2</sup>
Morris et al. 2005 [7]	Cross-sectional USA <i>Low risk</i>	1550 (47%) 68	Osteoporosis: 11.5 (10.3–12.7) Osteopenia: 10.2 (9.5–10.8) Normal: 10.0 (9.6–10.5) Geometric mean (95% CI)	BMD: Trochanter, intertrochanter, FN, Ward's triangle, TH [DXA, Hologic QDR-1000]	OR (95% CI) for mean BMD in relation to quartile categories of tHcy status + P for trend Category median ( $\mu\text{mol/L}$ ): Q1: 6.9 Q2: 8.9 Q3: 10.8 Q4: 14.8	Q1: 1.0 (reference) Q2: 0.9 (0.4–1.9) Q3: 2.0 (0.7–5.1) Q4: 2.0 (0.8–4.9) P for trend = 0.09 <sup>5</sup> Dose response analysis: subjects with tHcy level >20 $\mu\text{mol/L}$ had sign lower BMD than subj with tHcy level <10 $\mu\text{mol/L}$

TABLE 3: Continued.

Author Year	Study characteristics Duration of follow-up (when applicable) Country <i>Risk of bias</i>	Population characteristics: N (%men) Age (y) $\pm$ SD	Homocysteine status ( $\mu\text{mol/L}$ ) Mean $\pm$ SD	Outcome	Association type	Results
Ouzzif et al. 2012 [39]	Cross-sectional Morocco <i>Moderate risk</i>	188 (0%) 57.8 $\pm$ 8.5	12.4 $\pm$ 4.1	BMD: FN, LS, TH, trochanter [DXA, Lunar prodigy]	Multivariate regression, $\beta$ for association tHcy-BMD $\beta$ (SE) + P value	LS: -0.089 (0.003) $P = 0.200^1$ TH: -0.155 (0.002) $P = 0.021^1$
Périer et al. 2007 [27]	Cohort (cross-sect data) France <i>Moderate risk</i>	671 (0%) 61.6 $\pm$ 8.4	10.6 $\pm$ 3.5	BMD: FN, LS, TH [DXA, Hologic QDR-2000]	$\beta$ for association tHcy-BMD $\beta$ (SE)	LS: -0.000065 (0.0004) FN: -0.006 (0.004) TH: -0.006 (0.004) <sup>2</sup> Premenopausal women <sup>u,2</sup> ; LS: 0.20 (0.14) $P = 0.176$ FN: 0.17 (0.15) $P = 0.253$ TH: 0.20 (0.14) $P = 0.170$ Postmenopausal women <sup>u,2</sup> ; LS: 0.12 (0.15) $P = 0.439$ FN: 0.20 (0.15) $P = 0.181$ TH: 0.12 (0.14) $P = 0.391$
Rumbak et al. 2012 [40]	Cross-sectional Croatia <i>Low risk</i>	131 (0%) 54.0 $\pm$ 4.9	9.9 $\pm$ 2.0	BMD: FN, LS, TH, radius [DXA, Lunar-prodigy]	Stepwise multivariate regression, $\beta$ for association tHcy-BMD. $\beta$ (SE) for premenopausal and postmenopausal women	
Zhu et al. 2009 [31]	Cohort (5 y) Australia <i>Moderate risk</i>	1213 (0%) 75.2 $\pm$ 2.7	12.1 $\pm$ 4.6	BMD: TH [DXA, Hologic Acclaim 4500A]	Change in hip BMD from 1 to 5 years per tertile of tHcy ( $\mu\text{mol/L}$ ) ANOVA	Tertile 1 and 3 differ significantly ( $P < 0.05$ )

BMD sites—LS: Lumbar Spine, FN: Femoral Neck<sup>#</sup> data presented in article as nmol/L, this is presumably a typing error and should be  $\mu\text{mol/L}$ .

<sup>1</sup>data as provided by author on our request, <sup>2</sup> $\beta$  (SE) as calculated from presented data, <sup>3</sup> $\beta$  (SE) as calculated from data provided by author on our request.

<sup>a</sup>adjusted for age, BMI, smoking status, recurrent falling, serum creatinine; <sup>b</sup>adjusted for age and BMI; <sup>c</sup>adjusted for serum creatinine (natural log), B<sub>12</sub> level, folic acid level, BMI, smoking, walking speed, BMD, LnPTH; <sup>d</sup>adjusted for age, BMI, smoking, coffee intake, physical activity, vit D use, educational level, estrogen use in women; <sup>e</sup>case-control matched for age and ethnicity. Adjusted for BMI, parental history of hip fracture, treated diabetes, alcohol use, smoking, history of stroke, total calcium intake; <sup>f</sup>adjusted for sex, age, height, weight, smoking status, caffeine intake, alcohol intake, education level, estrogen use in women; <sup>g</sup>adjusted for sex, age, height, weight, estrogen use in women; <sup>h</sup>adjusted for age, sex, BMI, changes in BMI before entry in the study, smoking, fall history, serum creatinine; <sup>i</sup>adjusted for age, prevalent fractures, BMD, calcium intake, physical activity, vitamin D level, creatinine, albumin, estradiol; <sup>j</sup>adjusted for age, gender, education, serum creatinine, osteoporosis drugs; <sup>k</sup>adjusted for age, weight, hip BMD, prevalent fracture, calcium treatment; <sup>l</sup>adjusted for weight, cysteine, smoking and height; <sup>m</sup>Adjusted for duration of menopause, smoking, BMI, folic acid levels, homocysteine levels; <sup>n</sup>adjusted for age, BMI, logFolate, logB<sub>12</sub>, creatinine clearance; <sup>o</sup>Adjusted for age, weight, weight change; <sup>p</sup>Adjusted for BMI, smoking, age; <sup>q</sup>Adjusted for smoking, BMI, creatinine, coffee intake, physical activity, use of estrogen therapy; <sup>r</sup>adjusted for age, B<sub>12</sub>, folate, PTH, CTx, Ca, Cr; <sup>s</sup>adjusted for age, sex, ethnicity, BMI, smoking, physical activity, creatinin, alcohol, coffee, energy, calcium, vitamin D zinc intake; <sup>t</sup>adjusted for age, BMI, folate, B<sub>12</sub>; <sup>u</sup>adjusted for age, BMI, smoking, alcohol intake, physical activity, duration of menopause, HRT, levels of hcy, vitB<sub>12</sub> and folate.



Only five studies regarding BMD included a male population [6, 7, 10, 35, 38], and these studies were not comparable quantitatively because differences in the presentation of results or differences in the measured BMD sites.

**3.2.1. Vitamin B<sub>12</sub>.** Pooled analysis showed no association between serum/plasma vitamin B<sub>12</sub> levels and BMD in women; FN:  $\beta = 0.00$ , 95% CI:  $-0.13$  to  $0.14$ ,  $I^2 = 0\%$ ,  $P = 0.40$  [9, 37, 40]; LS:  $\beta = -2.25$ , 95% CI:  $-7.98$  to  $3.49$ ,  $I^2 = 99.5\%$ ,  $P < 0.0001$  [9, 37, 39, 40]; total hip  $\beta = -2.23$ , 95% CI:  $-10.38$  to  $5.92$ ,  $I^2 = 97.7\%$ , and  $P = 0.0001$  [33, 37, 39, 40]. The studies that could not be included in the meta-analyses showed diverse results; in six out of eight studies low serum/plasma vitamin B<sub>12</sub> was significantly associated with low BMD at at least one site [6, 7, 11, 32, 35, 38]. Two studies did not observe an association between vitamin B<sub>12</sub> status and BMD [34, 36]. Morris et al. addressed MMA levels as well as a marker for vitamin B<sub>12</sub> status and observed a lower BMD with higher serum MMA concentrations [7].

**3.2.2. Folate.** Pooled analysis showed no association between serum/plasma folate and BMD in women; FN:  $\beta = 0.00$ , 95% CI:  $-0.03$  to  $0.03$ ,  $I^2 = 0.00\%$ ,  $P = 0.88$  [9, 37, 40]; LS:  $\beta = 0.01$ , 95% CI:  $0.00$  to  $0.01$ ,  $I^2 = 0\%$ ,  $P = 0.77$  [9, 37, 39, 40]; total hip:  $\beta = 0.00$ , 95% CI:  $0.00$  to  $0.01$ ,  $I^2 = 78.5\%$ ,  $P = 0.0003$  [10, 33, 37, 39, 40].

From the studies that could not be compared in a meta-analysis, three studies showed significant associations between folate status and BMD or change in BMD over time [8, 10, 34]. Five studies did not observe an association between folate status and BMD [7, 32, 36, 38, 41].

**3.2.3. Homocysteine.** Pooled analyses showed no association between serum/plasma homocysteine levels and BMD in women; FN:  $\beta = -0.01$ , 95% CI:  $-0.04$  to  $0.02$ ,  $I^2 = 31.5\%$ ,  $P = 0.21$  [9, 27, 37, 40]; LS:  $\beta = -0.01$ , 95% CI:  $-0.08$  to  $0.05$ ,  $I^2 = 98.4\%$ ,  $P < 0.0001$  [9, 27, 37, 39, 40]; total hip:  $\beta = -0.03$ , 95% CI:  $-0.08$  to  $0.02$ ,  $I^2 = 99.9\%$ ,  $P < 0.0001$  [10, 27, 33, 37, 39, 40]. The studies that could not be pooled showed diverse results. In five studies a high homocysteine level was significantly associated with low BMD or change in BMD over time at at least one site [7, 29, 31, 32, 41]. Three studies did not observe a significant association between homocysteine status and BMD or change in BMD [8, 34, 36].

**3.3. Intervention Studies.** Up until now, only one RCT ( $N = 47$ ) which met our inclusion criteria studied the efficacy of B-vitamin supplementation on BMD [42]. This study shows some evidence that BMD may be increased with high doses of B-vitamin supplementation in people with hyperhomocysteinemia ( $tHcy > 15 \mu\text{mol/L}$ ). However, this outcome was only found in a subanalysis of 8 hyperhomocysteinemic subjects [42].

## 4. Discussion

Our meta-analyses showed a significant association of homocysteine levels with fracture risk and a weak though

significant inverse association of vitamin B<sub>12</sub> levels with fracture risk. We could not draw a conclusion regarding folate levels and fracture risk, as too few studies investigated this association. Meta-analyses regarding vitamin B<sub>12</sub>, folate and homocysteine levels and BMD in women found no associations. Results from studies regarding BMD that could not be included in the meta-analyses are not univocal.

To our knowledge this systematic review with meta-analyses is the most extensive systematic review on the association of vitamin B<sub>12</sub>, folate and homocysteine with bone health until now. Previous non-systematic literature reviews on the association between folate, vitamin B<sub>12</sub>, and homocysteine with bone health reported similar results, that is, conflicting evidence with suggestions towards the association of homocysteine levels with fracture [43–45]. These reviews did not report a systematic literature search strategy and did not provide a quantitative cumulative result. In our review the most recent published articles have been taken into account. The search strategy we used was systematic and extensive, and we used well-defined in- and exclusion criteria.

One recent systematic review included a meta-analysis on the association between  $tHcy$  and fractures [20]. This meta-analysis is different in design than ours, as it is not a dose-response meta-analysis. To overcome the variation in cut-off levels for low vitamin B<sub>12</sub> and folate status and high homocysteine status, and to allow comparison and subsequent combination of individual studies in the performed meta-analyses, we expressed results of individual studies in a standardized format. We assumed a linear, continuous dose-response association between markers of vitamin B<sub>12</sub> and folate with fracture rather than a threshold effect. This assumption is generally used in meta-analyses. Furthermore, in some of the key articles addressing the association of homocysteine levels with fractures this association is present [4, 5].

A common concern in meta-analyses is heterogeneity between studies. In our meta-analyses we experienced various levels of statistical heterogeneity (no heterogeneity to large heterogeneity). The heterogeneity may be explained by the differences in mean age of the study populations (41–78 years), differences in mean status of vitamin B<sub>12</sub> (190–549 pmol/L), folate (5.2–24.9 nmol/L) and homocysteine (9.3–16.5  $\mu\text{mol/L}$ ), differences in sex distribution of the study populations, duration of follow-up (3–16 years), and level of adjustment for confounders. Although most included studies adjusted for a wide range of confounders for fracture risk or BMD, residual confounding by other unmeasured or inadequately measured factors cannot be ruled out. For example, low vitamin D status is a risk factor for fracture [46]. From the studies included in our meta-analyses for fracture three out of nine adjusted for vitamin D status [24, 25, 27]. Outcomes do not seem to differ between studies that corrected for vitamin D status and studies that did not. Homocysteine levels are increased with renal dysfunction, often measured by serum or urine creatinine levels. Five out of eight studies in the meta-analysis regarding homocysteine and fracture risk corrected for creatinine levels [3, 24, 26, 27, 29], and outcomes did not seem to differ.

As almost all studies were performed in countries without mandatory folate fortification or were performed before

the fortification era in the USA and Australia, we do not consider folate fortification as a source of heterogeneity in our analyses.

The majority of studies included were longitudinal and cross-sectional observational studies. We could only include one intervention study, which had a very small study population ( $N = 47$ ). One intervention study which found a beneficial effect of vitamin B<sub>12</sub> and folic acid supplementation on fracture risk could not be included in our systematic review, because this study investigated a population of hemiplegic patients following stroke [47]. The generalizability of these findings is confined to a highly selective patient population with a high percentage of vitamin D deficiency and a high fracture risk. As evidence from intervention studies is lacking, currently no causal effect between vitamin B<sub>12</sub>, folate and homocysteine levels and bone health can be established. Consequently, it is yet unknown whether extra vitamin B<sub>12</sub> and folate intake through supplementation could reverse the observed negative effects of vitamin B<sub>12</sub> and folate deficiency and elevated homocysteine levels. Further evidence from an intervention study is expected soon, as a large intervention study on the effect of vitamin B<sub>12</sub> and folic acid supplementation on fracture risk, BMD, and bone turnover markers is currently carried out with results expected in 2013 [48].

As the quality of included studies determines the quality of the review and meta-analysis, we assessed the overall risk of bias of each individual study using standardized procedures largely based on guidance from the Cochrane Collaboration [49], resulting in one of the following judgments: low, moderate, or high risk of bias. Twenty out of the 28 included studies were evaluated as having moderate ( $n = 15$ ) or high risk ( $n = 5$ ) of bias. These studies did take one or more of the predefined confounders into account, that is, age, sex, smoking, physical activity, and body weight, or the study was funded or cofunded by a commercial organization. Due to the limited number of studies included in the meta-analyses, we were not able to study the effect of the overall risk of bias, nor of its single components on the pooled effect measures. There seems to be no difference in the outcomes of studies with low risk of bias compared to studies with moderate or high risk of bias, and we therefore assume that the quality of the included studies had no effect on the outcome of this review.

The intake of folate and vitamin B<sub>12</sub> are a determinant of folate, vitamin B<sub>12</sub>, and homocysteine status. To deal with potential malabsorption of vitamin B<sub>12</sub> [50] and reduced bioavailability of folate [51], the use of biomarkers for vitamin B<sub>12</sub> and folate status is preferred over measures of intake when studying associations with bone health in elderly people.

In studies addressing folate status, serum or plasma folate was measured, which is considered as an appropriate marker for folate status in epidemiological studies [52]. Homocysteine is a nonspecific marker for both folate and vitamin B<sub>12</sub> status [53], which makes it a relevant biomarker in this review. Regarding the metabolic interactions between vitamin B<sub>12</sub>, folate, and homocysteine combined with the variety in data presented in the studies, we were not able

to investigate the possibility that a low vitamin B<sub>12</sub> or folate status in combination with a high homocysteine level might result in a higher fracture risk in comparison to a low vitamin B<sub>12</sub> or folate status or homocysteine level alone. In most studies regarding vitamin B<sub>12</sub> status, status was assessed with serum or plasma vitamin B<sub>12</sub>. Other, more sensitive markers for vitamin B<sub>12</sub> deficiency, like MMA and HoloTC [54], were addressed only in a few studies. We could therefore not draw conclusions about the association between these biomarkers and outcomes on bone health.

There are several suggested mechanisms for the association between vitamin B<sub>12</sub>, folate, homocysteine, and bone health. Homocysteine may interfere with collagen cross-linking. Cross-links are important for the stability and strength of the collagen network. Interference in cross-link formation would cause an altered bone matrix, resulting in more fragile bones [55]. As collagen cross-links do not alter BMD, this may explain why a more convincing result is found regarding fractures than BMD, as suggested for example by Van Meurs et al. [5]. Vitamin B<sub>12</sub> deficiency has been associated with impaired functional maturation of osteoblasts [56]. Some *in vitro* studies support the hypothesis of a possible favorable effect of vitamin B<sub>12</sub> supplementation, although results are equivocal. Vitamin B<sub>12</sub> has been shown to stimulate osteoblast proliferation and alkaline phosphatase activity [57] but Herrmann et al. were not able to show any significant and consistent effect of vitamin B<sub>12</sub> or folic acid on osteoblast activity [58]. Recent publications show evidence of osteoclast stimulation in the presence of high homocysteine and low vitamin B<sub>12</sub> concentrations [59–61]. Vitamin B<sub>12</sub> and folate are not the only B-vitamins involved in the homocysteine metabolism. Various micronutrients, such as vitamin B<sub>2</sub> (riboflavin), vitamin B<sub>6</sub> (pyridoxine), and choline also affect homocysteine levels [16, 17, 62], and may consequently affect bone health. Given that vitamin B<sub>12</sub> and folate are the main factors influencing homocysteine levels, and therefore the primary focus in a homocysteine lowering intervention [63], our review focused on vitamin B<sub>12</sub>, folate, and homocysteine.

*Considerations for Future Research and Conclusions.* The mechanisms involved in the association between biomarkers of B-vitamins and bone health are still unclear and therefore more fundamental research is required to establish the potential mechanisms. Subsequently, both observational and intervention studies should preferably not focus on just one biomarker in relation to the homocysteine metabolism, but take a biomarker profile into account, including serum/plasma vitamin B<sub>12</sub>, MMA, HoloTC, folate, and homocysteine levels. Evidence is needed from well-designed, large intervention studies to establish a causal relationship between markers of B-vitamins and bone health.

This systematic review with meta-analyses shows that elevated homocysteine levels are associated with increased fracture risk. Vitamin B<sub>12</sub> status may be associated with fracture risk and evidence for an association between folate status and fracture risk is scarce. Vitamin B<sub>12</sub>, folate, and homocysteine levels are probably not associated with BMD, but results are not univocal.

## Acknowledgments

The work reported herein has been carried out within the EURRECA Network of Excellence (<http://www.eurreca.org/>) which is financially supported by the Commission of the European Communities, specific Research, Technology and Development (RTD) Programme Quality of Life and Management of Living Resources, within the Sixth Framework Programme, Contract no. 036196. This review does not necessarily reflect the Commission's views or its future policy in this area. The original conception of the systematic review was undertaken by the EURRECA Network and coordinated by partners based at Wageningen University (WU), the Netherlands and the University of East Anglia (UEA), United Kingdom. Susan Fairweather-Tait (UEA), C. P. G. M. de Groot (WU), P. van't Veer (WU), Kate Ashton (UEA), Amélie Casgrain (UEA), A. E. J. M. Cavelaars (WU), Rachel Collings (UEA), R. A. M. Dhonukshe-Rutten (WU), E. L. Doets (WU), Linda Harvey (UEA), and Lee Hooper (UEA) designed and developed the review protocol and search strategy. The authors thank Silvia Bell, Iris Iglesias (University of Zaragoza, Spain), Maria Plada (University of Athens, Greece), Nathalie van Borrendam, and Margreet Smit (Wageningen University, the Netherlands) for assistance in article selection and data extraction. Furthermore The authors thank Dr. RAM Dhonukshe-Rutten, Department of Human nutrition, Wageningen University, The Netherlands, Dr. A. Cagnacci, Department of Obstetrics, Gynecology and Pediatrics, Obstetrics and Gynecology Unit, Policlinico of Modena, Modena, Italy, R. R. McLean, Dsc, MPH, Institute for Aging Research, Hebrew SeniorLife, Boston, MA, USA, Harvard Medical School, Boston, MA, USA, and Dr. E. Sarnay-Rendu, INSERM, France, for providing the authors with additional data regarding their articles.

## References

- [1] "Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis," *The American Journal of Medicine*, vol. 94, no. 6, pp. 646–650, 1993.
- [2] J. A. Kanis and O. Johnell, "Requirements for DXA for the management of osteoporosis in Europe," *Osteoporosis International*, vol. 16, no. 3, pp. 229–238, 2005.
- [3] R. A. M. Dhonukshe-Rutten, S. M. F. Pluijm, L. C. P. G. M. De Groot, P. Lips, J. H. Smit, and W. A. Van Staveren, "Homocysteine and vitamin B12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people," *Journal of Bone and Mineral Research*, vol. 20, no. 6, pp. 921–929, 2005.
- [4] R. R. McLean, P. F. Jacques, J. Selhub et al., "Homocysteine as a predictive factor for hip fracture in older persons," *The New England Journal of Medicine*, vol. 350, no. 20, pp. 2042–2049, 2004.
- [5] J. B. van Meurs, R. A. Dhonukshe-Rutten, S. M. Pluijm et al., "Homocysteine levels and the risk of osteoporotic fracture," *The New England Journal of Medicine*, vol. 350, no. 20, pp. 2033–2041, 2004.
- [6] K. L. Tucker, M. T. Hannan, N. Qiao et al., "Low plasma vitamin B12 is associated with lower BMD: The Framingham osteoporosis study," *Journal of Bone and Mineral Research*, vol. 20, no. 1, pp. 152–158, 2005.
- [7] M. S. Morris, P. F. Jacques, and J. Selhub, "Relation between homocysteine and B-vitamin status indicators and bone mineral density in older Americans," *Bone*, vol. 37, no. 2, pp. 234–242, 2005.
- [8] A. Cagnacci, F. Baldassari, G. Rivolta, S. Arangino, and A. Volpe, "Relation of homocysteine, folate, and vitamin B12 to bone mineral density of postmenopausal women," *Bone*, vol. 33, no. 6, pp. 956–959, 2003.
- [9] J. Golbahar, A. Hamidi, M. A. Aminzadeh, and G. R. Omrani, "Association of plasma folate, plasma total homocysteine, but not methylenetetrahydrofolate reductase C667T polymorphism, with bone mineral density in postmenopausal Iranian women: a cross-sectional study," *Bone*, vol. 35, no. 3, pp. 760–765, 2004.
- [10] C. G. Gjesdal, S. E. Vollset, P. M. Ueland et al., "Plasma total homocysteine level and bone mineral density: The Hordaland Homocysteine Study," *Archives of Internal Medicine*, vol. 166, no. 1, pp. 88–94, 2006.
- [11] K. L. Stone, D. C. Bauer, D. Sellmeyer, and S. R. Cummings, "Low serum vitamin B-12 levels are associated with increased hip bone loss in older women: a prospective study," *Journal of Clinical Endocrinology and Metabolism*, vol. 89, no. 3, pp. 1217–1221, 2004.
- [12] A. de Bree, N. M. van der Put, L. I. Mennen et al., "Prevalences of hyperhomocysteinemia, unfavorable cholesterol profile and hypertension in European populations," *European Journal of Clinical Nutrition*, vol. 59, no. 4, pp. 480–488, 2005.
- [13] W. Wouters-Wesseling, A. E. J. Wouters, C. N. Kleijer, J. G. Bindels, C. P. G. M. de Groot, and W. A. van Staveren, "Study of the effect of a liquid nutrition supplement on the nutritional status of psycho-geriatric nursing home patients," *European Journal of Clinical Nutrition*, vol. 56, no. 3, pp. 245–251, 2002.
- [14] S. J. P. M. Eussen, L. C. P. G. M. De Groot, R. Clarke et al., "Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: a dose-finding trial," *Archives of Internal Medicine*, vol. 165, no. 10, pp. 1167–1172, 2005.
- [15] R. Green, "Indicators for assessing folate and vitamin B-12 status and for monitoring the efficacy of intervention strategies," *American Journal of Clinical Nutrition*, vol. 94, no. 2, pp. 666S–672S, 2011.
- [16] J. Selhub, P. F. Jacques, P. W. F. Wilson, D. Rush, and I. H. Rosenberg, "Vitamin status and intake as primary determinants of homocysteinemia in an elderly population," *Journal of the American Medical Association*, vol. 270, no. 22, pp. 2693–2698, 1993.
- [17] P. F. Jacques, A. G. Bostom, P. W. F. Wilson, S. Rich, I. H. Rosenberg, and J. Selhub, "Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort," *American Journal of Clinical Nutrition*, vol. 73, no. 3, pp. 613–621, 2001.
- [18] R. Clarke, "Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials," *British Medical Journal*, vol. 316, no. 7135, pp. 894–898, 1998.
- [19] A. M. Kuzminski, E. J. Del Giacco, R. H. Allen, S. P. Stabler, and J. Lindenbaum, "Effective treatment of cobalamin deficiency with oral cobalamin," *Blood*, vol. 92, no. 4, pp. 1191–1198, 1998.
- [20] J. Yang, X. Hu, Q. Zhang, H. Cao, J. Wang, and B. Liu, "Homocysteine level and risk of fracture: a meta-analysis and systematic review," *Bone*, vol. 51, no. 3, pp. 376–382, 2012.



- [21] C. Matthys, P. van't Veer, L. de Groot et al., "EURRECA's approach for estimating micronutrient requirements," *International Journal for Vitamin and Nutrition Research*, vol. 81, no. 4, pp. 256–263, 2011.
- [22] O. W. Souverein, C. Dullemeijer, P. van't Veer, and H. van der Voet, "Transformations of summary statistics as input in meta-analysis for linear dose-response models on a logarithmic scale: a methodology developed within EURRECA," *BMC Medical Research Methodology*, vol. 12, no. 1, article 57, 2012.
- [23] R. DerSimonian and N. Laird, "Meta-analysis in clinical trials," *Controlled Clinical Trials*, vol. 7, no. 3, pp. 177–188, 1986.
- [24] C. G. Gjesdal, S. E. Vollset, P. M. Ueland, H. Refsum, H. E. Meyer, and G. S. Tell, "Plasma homocysteine, folate, and vitamin B12 and the risk of hip fracture: the hordaland homocysteine study," *Journal of Bone and Mineral Research*, vol. 22, no. 5, pp. 747–756, 2007.
- [25] R. R. McLean, P. F. Jacques, J. Selhub et al., "Plasma B vitamins, homocysteine, and their relation with bone loss and hip fracture in elderly men and women," *Journal of Clinical Endocrinology and Metabolism*, vol. 93, no. 6, pp. 2206–2212, 2008.
- [26] G. Ravaglia, P. Forti, F. Maioli et al., "Folate, but not homocysteine, predicts the risk of fracture in elderly persons," *Journals of Gerontology A*, vol. 60, no. 11, pp. 1458–1462, 2005.
- [27] M. A. Périer, E. Gineyts, F. Munoz, E. Sornay-Rendu, and P. D. Delmas, "Homocysteine and fracture risk in postmenopausal women: The OFELY study," *Osteoporosis International*, vol. 18, no. 10, pp. 1329–1336, 2007.
- [28] M. S. Leboff, R. Narweker, A. Lacroix et al., "Homocysteine levels and risk of hip Fracture in postmenopausal women," *Journal of Clinical Endocrinology and Metabolism*, vol. 94, no. 4, pp. 1207–1213, 2009.
- [29] P. Gerdhem, K. K. Ivaska, A. Isaksson et al., "Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women," *Journal of Bone and Mineral Research*, vol. 22, no. 1, pp. 127–134, 2007.
- [30] A. W. Enneman, N. van der Velde, R. de Jonge et al., "The association between plasma homocysteine levels, methylation capacity and incident osteoporotic fractures," *Bone*, vol. 50, no. 6, pp. 1401–1405, 2012.
- [31] K. Zhu, J. Beilby, I. M. Dick, A. Devine, M. Soós, and R. L. Prince, "The effects of homocysteine and MTHFR genotype on hip bone loss and fracture risk in elderly women," *Osteoporosis International*, vol. 20, no. 7, pp. 1183–1191, 2009.
- [32] N. Bozkurt, M. Erdem, E. Yilmaz et al., "The relationship of homocysteine, B12 and folic acid with the bone mineral density of the femur and lumbar spine in Turkish postmenopausal women," *Archives of Gynecology and Obstetrics*, vol. 280, no. 3, pp. 381–387, 2009.
- [33] P. Bucciarelli, G. Martini, I. Martinelli et al., "The relationship between plasma homocysteine levels and bone mineral density in post-menopausal women," *European Journal of Internal Medicine*, vol. 21, no. 4, pp. 301–305, 2010.
- [34] A. Cagnacci, B. Bagni, A. Zini, M. Cannoletta, M. Generali, and A. Volpe, "Relation of folates, vitamin B12 and homocysteine to vertebral bone mineral density change in postmenopausal women: a five-year longitudinal evaluation," *Bone*, vol. 42, no. 2, pp. 314–320, 2008.
- [35] R. A. M. Dhonukshe-Rutten, M. Lips, N. De Jong et al., "Vitamin B-12 status is associated with bone mineral content and bone mineral density in frail elderly women but not in men," *Journal of Nutrition*, vol. 133, no. 3, pp. 801–807, 2003.
- [36] B. Haliloglu, F. B. Aksungar, E. Ilter et al., "Relationship between bone mineral density, bone turnover markers and homocysteine, folate and vitamin B12 levels in postmenopausal women," *Archives of Gynecology and Obstetrics*, vol. 281, no. 4, pp. 663–668, 2010.
- [37] Z. Krivosikova, M. Krajčovičová-Kudláčková, V. Spustová et al., "The association between high plasma homocysteine levels and lower bone mineral density in Slovak women: the impact of vegetarian diet," *European Journal of Nutrition*, vol. 49, no. 3, pp. 147–153, 2010.
- [38] I. Naharci, E. Bozoglu, N. Karadurmus et al., "Vitamin B12 and folic acid levels as therapeutic target in preserving bone mineral density (BMD) of older men," *Archives of Gerontology and Geriatrics*, vol. 54, no. 3, pp. 469–472, 2012.
- [39] Z. Ouzzif, K. Oumghar, K. Sbai, A. Mounach, E. M. Derouiche, and A. El Maghraoui, "Relation of plasma total homocysteine, folate and vitamin B12 levels to bone mineral density in Moroccan healthy postmenopausal women," *Rheumatology International*, vol. 32, no. 1, pp. 123–128, 2012.
- [40] I. Rumbak, V. Ziic, L. Sokolic, S. Cvijetic, R. Kajfe, and I. Colic Baric, "Bone mineral density is not associated with homocysteine level, folate and vitamin B12 status," *Archives of Gynecology and Obstetrics*, vol. 285, no. 4, pp. 991–1000, 2012.
- [41] M. Baines, M. B. Kredan, A. Davison et al., "The association between cysteine, bone turnover, and low bone mass," *Calcified Tissue International*, vol. 81, no. 6, pp. 450–454, 2007.
- [42] M. Herrmann, N. Umanskaya, L. Traber et al., "The effect of B-vitamins on biochemical bone turnover markers and bone mineral density in osteoporotic patients: a 1-year double blind placebo controlled trial," *Clinical Chemistry and Laboratory Medicine*, vol. 45, no. 12, pp. 1785–1792, 2007.
- [43] M. Herrmann, J. Peter Schmidt, N. Umanskaya et al., "The role of hyperhomocysteinemia as well as folate, vitamin B6 and B12 deficiencies in osteoporosis—a systematic review," *Clinical Chemistry and Laboratory Medicine*, vol. 45, no. 12, pp. 1621–1632, 2007.
- [44] R. R. McLean and M. T. Hannan, "B vitamins, homocysteine, and bone disease: epidemiology and pathophysiology," *Current Osteoporosis Reports*, vol. 5, no. 3, pp. 112–119, 2007.
- [45] R. Levasseur, "Bone tissue and hyperhomocysteinemia," *Joint Bone Spine*, vol. 76, no. 3, pp. 234–240, 2009.
- [46] P. Lips and N. M. van Schoor, "The effect of vitamin D on bone and osteoporosis," *Best Practice & Research*, vol. 25, no. 4, pp. 585–591, 2011.
- [47] Y. Sato, Y. Honda, J. Iwamoto, T. Kanoko, and K. Satoh, "Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial," *Journal of the American Medical Association*, vol. 293, no. 9, pp. 1082–1088, 2005.
- [48] J. P. van Wijngaarden, R. A. Dhonukshe-Rutten, N. M. van Schoor et al., "Rationale and design of the B-PROOF study, a randomized controlled trial on the effect of supplemental intake of vitamin B12 and folic acid on fracture incidence," *BMC Geriatrics*, vol. 11, no. 1, article 80, 2011.
- [49] J. Higgins and S. Green, *Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0*, The Cochrane Collaboration, 2011.
- [50] L. H. Allen, "How common is vitamin B-12 deficiency?" *The American Journal of Clinical Nutrition*, vol. 89, no. 2, pp. 693S–696S, 2009.

- [51] H. McNulty and K. Pentieva, "Folate bioavailability," *Proceedings of the Nutrition Society*, vol. 63, no. 4, pp. 529–536, 2004.
- [52] E. A. Yetley, P. M. Coates, and C. L. Johnson, "Overview of a roundtable on NHANES monitoring of biomarkers of folate and vitamin B-12 status: measurement procedure issues," *American Journal of Clinical Nutrition*, vol. 94, no. 1, pp. 297S–302S, 2011.
- [53] R. Carmel, R. Green, D. S. Rosenblatt, and D. Watkins, "Update on cobalamin, folate, and homocysteine," *Hematology*, pp. 62–81, 2003.
- [54] L. Hoey, J. J. Strain, and H. McNulty, "Studies of biomarker responses to intervention with vitamin B-12: a systematic review of randomized controlled trials," *American Journal of Clinical Nutrition*, vol. 89, no. 6, pp. 1981S–1996S, 2009.
- [55] M. Saito, K. Fujii, and K. Marumo, "Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls," *Calcified Tissue International*, vol. 79, no. 3, pp. 160–168, 2006.
- [56] R. Carmel, K. H. W. Lau, D. J. Baylink, S. Saxena, and F. R. Singer, "Cobalamin and osteoblast-specific proteins," *The New England Journal of Medicine*, vol. 319, no. 2, pp. 70–75, 1988.
- [57] G. S. Kim, C. H. Kim, J. Y. Park, K. U. Lee, and C. S. Park, "Effects of vitamin B12 on cell proliferation and cellular alkaline phosphatase activity in human bone marrow stromal osteoprogenitor cells and UMR106 osteoblastic cells," *Metabolism: Clinical and Experimental*, vol. 45, no. 12, pp. 1443–1446, 1996.
- [58] M. Herrmann, N. Umanskaya, B. Wildemann et al., "Accumulation of homocysteine by decreasing concentrations of folate, vitamin B12 and B6 does not influence the activity of human osteoblasts in vitro," *Clinica Chimica Acta*, vol. 384, no. 1-2, pp. 129–134, 2007.
- [59] M. Herrmann, T. Widmann, G. Colaianni, S. Colucci, A. Zallone, and W. Herrmann, "Increased osteoclast activity in the presence of increased homocysteine concentrations," *Clinical Chemistry*, vol. 51, no. 12, pp. 2348–2353, 2005.
- [60] B. L. T. Vaes, C. Lute, H. J. Blom et al., "Vitamin B12 deficiency stimulates osteoclastogenesis via increased homocysteine and methylmalonic acid," *Calcified Tissue International*, vol. 84, no. 5, pp. 413–422, 2009.
- [61] B. L. T. Vaes, C. Lute, S. P. van der Woning et al., "Inhibition of methylation decreases osteoblast differentiation via a non-DNA-dependent methylation mechanism," *Bone*, vol. 46, no. 2, pp. 514–523, 2010.
- [62] P. I. Holm, P. M. Ueland, S. E. Vollset et al., "Betaine and folate status as cooperative determinants of plasma homocysteine in humans," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 25, no. 2, pp. 379–385, 2005.
- [63] R. Clarke and J. Armitage, "Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements," *Seminars in Thrombosis and Hemostasis*, vol. 26, no. 3, pp. 341–348, 2000.